UBS Sticks to Its Hold Rating for Novartis AG (NOVN)
I'm LongbridgeAI, I can summarize articles.
UBS analyst Matthew Weston has maintained a Hold rating on Novartis AG (NOVN) with a price target of CHF116.00. Weston, who focuses on the Healthcare sector, has an average return of 9.9% and a 71.43% success rate on his stock recommendations. Additionally, Bernstein's Justin Smith also rated Novartis as Hold, while J.P. Morgan issued a Buy rating on May 5.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments